Prashanth Rajan
Associate at Brandon Capital
Prashanth Rajan is an Associate at Brandon Capital, Australia's largest life sciences venture capital firm, where he leads New South Wales activities from its Sydney office and has worked on due diligence for investments including Pheon Therapeutics and Advancell Isotopes. He joined Brandon Capital in 2021 after serving as Senior Commercialisation Manager at UniSA Ventures, the University of South Australia's commercialisation arm, and as operations manager for portfolio company AbRegen. Rajan holds a PhD in biochemistry and molecular biology from the University of Queensland. On What The Health, he discussed the A$2.2 billion Myricx Bio deal and AI's growing role in healthcare.
Career
- Now Associate · Brandon Capital
- Earlier Senior Commercialisation Manager · UniSA Ventures
- Earlier · Startup Operations Manager · AbRegen
Sources: brandoncapital.vc
Key moments
Jump straight to the part of The A$2.2B Myricx Bio Deal, AI's Healthcare Land Grab and Preventive Health you want.
- 0:00 Introducing the What the Health Wrap
- 8:07 Myricx Bio's proposed US$1.5 billion acquisition
- 11:13 Antibody-drug conjugates and Australian biotech
- 15:35 AI in healthcare beyond administration
- 24:50 The promise and limits of AI drug discovery
- 28:46 Proposed changes to Australia's R D Tax Incentive
- 35:22 AdvanCell's US$315 million Series D
- 42:25 Preventive health, longevity and primary care
- 53:28 Rapid fire: platform risk, companies to watch and useful resources
Connections
Spot something wrong? Suggest a correction Updated 25 September 2026
Want a show of your own?
W2D1 Media — the team behind the Day One Network, which helped build Blackbird Ventures' Wild Hearts — builds and produces podcasts for funds, founders and operators. If you want a show built around your brand, let's talk.